Dr. Abida on next steps with PARP inhibitors in prostate cancer

Video

Wassim Abida, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses what the next steps should be with PARP inhibitors in prostate cancer. The PARP inhibitors olaparib (Lynparza) and rucaparib (Rubraca) are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer, and other PARP agents are moving through the pipeline.

Related Videos
Todd M. Morgan, MD, answers a question during a Zoom video interview
3D illustration of prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Matthew Loria answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Man talking with doctor | Image Credit: © DragonImages - stock.adobe.com
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.